A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.Jian Li, Lin Shen, Dong Wang et al.|Journal of Clinical Oncology|2021Cited by 15
Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.Jian Li, Lin Shen, Ye Xu et al.|Journal of Clinical Oncology|2022Cited by 5
1057P Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumorsJ. Li, Lin Shen, Ye Xu et al.|Annals of Oncology|2023Cited by 0